Scribd Logo
Upload

Welcome to Scribd!

  • 52 views

    Cabergoline PDF

    Uploaded by

    Bebel Mantali
    Cabergoline is prescribed to treat hyperprolactinemia. It works by inhibiting the secretion of prolactin through its action as a dopamine agonist. Nurses should monitor the patient's blood pressure frequently during initial therapy due to the risk of hypotension. They should also evaluate the patient's cardiac status and monitor for signs of pulmonary or cardiac fibrosis during long-term therapy. The goals are to decrease galactorrhea in patients with hyperprolactinemia and maintain a normal serum prolactin level.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Cabergoline PDF

    Uploaded by

    Bebel Mantali
    52 views2 pages
    Cabergoline is prescribed to treat hyperprolactinemia. It works by inhibiting the secretion of prolactin through its action as a dopamine agonist. Nurses should monitor the patient's blood pressure frequently during initial therapy due to the risk of hypotension. They should also evaluate the patient's cardiac status and monitor for signs of pulmonary or cardiac fibrosis during long-term therapy. The goals are to decrease galactorrhea in patients with hyperprolactinemia and maintain a normal serum prolactin level.

    Original Title

    cabergoline.pdf

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Cabergoline is prescribed to treat hyperprolactinemia. It works by inhibiting the secretion of prolactin through its action as a dopamine agonist. Nurses should monitor the patient's blood pressure frequently during initial therapy due to the risk of hypotension. They should also evaluate the patient's cardiac status and monitor for signs of pulmonary or cardiac fibrosis during long-term therapy. The goals are to decrease galactorrhea in patients with hyperprolactinemia and maintain a normal serum prolactin level.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    52 views2 pages

    Cabergoline PDF

    Uploaded by

    Bebel Mantali
    Cabergoline is prescribed to treat hyperprolactinemia. It works by inhibiting the secretion of prolactin through its action as a dopamine agonist. Nurses should monitor the patient's blood pressure frequently during initial therapy due to the risk of hypotension. They should also evaluate the patient's cardiac status and monitor for signs of pulmonary or cardiac fibrosis during long-term therapy. The goals are to decrease galactorrhea in patients with hyperprolactinemia and maintain a normal serum prolactin level.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    You are on page 1of 2

    Name /bks_53161_deglins_md_disk/cabergoline 02/11/2014 09:24AM Plate # 0-Composite pg 1 # 1

    1 Adverse Reactions/Side Effects


    CNS: dizziness, headache, depression, drowsiness, fatigue, nervousness, vertigo, PDF Page #1
    cabergoline (ka-ber-goe-leen) weakness. Resp: PULMONARY FIBROSIS, pleural effusion. EENT: abnormal vision.
    Dostinex CV: PERICARDIAL FIBROSIS, VALVULAR DISORDERS, postural hypotension, hot flashes.
    Classification GI: RETROPERITONEAL FIBROSIS, constipation, nausea, abdominal pain, dyspepsia,
    Therapeutic: antihyperprolactinemic vomiting. GU: dysmenorrhea. Endo: breast pain. Neuro: paresthesia.
    Pharmacologic: dopamine agonists
    Interactions
    Pregnancy Category B Drug-Drug:qrisk of hypotension with antihypertensives. Mayqthe effects of
    SSRIs and other serotonin agonists (induces serotonin syndrome). Effectiveness
    Indications may bepby phenothiazines, butyrophenones (haloperidol), thioxanthenes,
    Treatment of hyperprolactinemia (idiopathic or pituitary in origin). or metoclopramide (avoid concurrent use).
    Action Route/Dosage
    Inhibits secretion of prolactin by acting as a dopamine agonist. Therapeutic Ef- PO (Adults): 0.25 mg twice weekly; may beqat 4-wk intervals up to 1 mg twice
    fects: Decreased secretion of prolactin in hyperprolactinemia. weekly.
    Pharmacokinetics NURSING IMPLICATIONS
    Absorption: Well absorbed but undergoes extensive first-pass hepatic metabo-
    lism. Assessment
    Distribution: Widely distributed; concentrates in pituitary. ● Monitor BP before and frequently during initial therapy. Initial doses ⬎1 m g may
    Metabolism and Excretion: Extensively metabolized by the liver; ⬍4% excreted cause orthostatic hypotension. Use with caution when administering concurrently
    unchanged in urine. with other medications that lower BP. Supervise ambulation and transfer during
    Protein Binding: 40– 42%. initial dosing to prevent injury from hypotension.
    Half-life: 63– 69 hr. ● Evaluate the cardiac status and monitor echocardiography at baseline
    TIME/ACTION PROFILE (effect on serum prolactin levels) and every 6– 12 mo after initiation of therapy or as indicated clinically
    ROUTE ONSET PEAK DURATION
    by signs and symptoms of valvular disease (dyspnea, edema, HF, new
    cardiac murmur). Use lowest dose and reassess need for therapy peri-
    PO unknown 2–3 hr unknown
    odically.
    Contraindications/Precautions ● Monitor for signs and symptoms of pulmonary fibrosis (dyspnea, per-
    Contraindicated in: Hypersensitivity to cabergoline or ergot alkaloids; Uncon- sistent coughing, difficulty with breathing while lying down, peripheral
    trolled hypertension; History of pulmonary, pericardial, or retroperitoneal fibrotic edema) periodically during therapy. Obtain chest x-ray prior to therapy
    disorders; History of cardiac valvular disease; Lactation: Has been associated with and chest x-ray and CT scan periodically during therapy to assess for
    hypertension, stroke, and seizures. Not to be used for suppression of physiologic lac- pulmonary fibrosis.
    tation. ● Lab Test Considerations: Monitor serum prolactin concentrations monthly
    Use Cautiously in: Hepatic impairment; Patients who have received medications until normalized (⬍20 mcg/L in women and ⬍15 mcg/L in men).
    associated with valvular disorders; OB: Use only if clearly needed; Pedi: Safety not ● Monitor erythrocyte sedimentation rate (ESR) and creatinine at baseline and as
    established. needed during therapy.
    ⫽ Canadian drug name. ⫽ Genetic Implication. CAPITALS indicate life-threatening, underlines indicate most frequent. Strikethrough ⫽ Discontinued.
    Name /bks_53161_deglins_md_disk/cabergoline 02/11/2014 09:24AM Plate # 0-Composite pg 2 # 2

    2
    Potential Nursing Diagnoses PDF Page #2
    Risk for injury (Side Effects)
    Impaired physical mobility (Indications)
    Implementation
    ● PO: May be taken without regard to food.

    Patient/Family Teaching
    ● Instruct patient to take medication as directed. Take missed doses as soon as pos-
    sible within 1 or 2 days. If not remembered until time of next dose, double dose. If
    nausea occurs, discuss with health care professional.
    ● May cause drowsiness and dizziness. Caution patient to avoid driving and other ac-
    tivities requiring alertness until response to medication is known.
    ● Advise patient to change positions slowly to minimize orthostatic hypotension.
    ● Caution patient to avoid concurrent use of alcohol during therapy.
    ● Instruct patients taking cabergoline for pituitary tumors to inform health care pro-
    fessional immediately if signs of tumor enlargement occur (blurred vision, sudden
    headache, severe nausea, and vomiting).
    ● Advise patient to notify health care professional if signs of valvular disorders
    (shortness of breath, swelling in extremities) occurs.
    ● Advise women to consult with health care professional regarding a nonhormonal
    method of birth control. Women should contact health care professional promptly
    if pregnancy is planned or suspected.
    ● Emphasize the importance of regular follow-up exams to determine effectiveness
    and monitor side effects.
    Evaluation/Desired Outcomes
    ● Decrease in galactorrhea in patients with hyperprolactinemia.
    ● After a normal serum prolactin level has been maintained for more than 6 mo, ca-
    bergoline may be discontinued. Serum prolactin levels should be monitored peri-
    odically to determine necessity of reinstituting cabergoline.
    Why was this drug prescribed for your patient?

    䉷 2015 F.A. Davis Company

    You might also like